The National Institute for Health and Care Excellence has published a trio of new final guidances, allowing National Health Service use of Boehringer Ingelheim’s Vargatef for lung cancer, AstraZeneca’s Moventig for opioid-induced constipation, and Novartis Cosentyx for plaque psoriasis.
Vargetef (nintedanib) is recommended as an option for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer that has progressed after first-line chemotherapy, but only if discounts agreed under a Patient Access Scheme are applied.
Moventig (naloxegol) has been endorsed as a cost-effective option for treating opioid-induced constipation in adults whose symptoms have not adequately responded to laxatives.
Cosentyx (secukinumab) was given the funding green light as an option for treating some adults with plaque psoriasis, but on the proviso that the company provides the drug at the discount agreed in PAS.
On the downside, Novartis’ Certican (everolimus) was turned down for preventing organ rejection in people having a liver transplant. NICE’s committee conceded the drug may offer some benefit in preserving kidney function, but ruled that it cost too much compared to current treatments already available on the NHS.
NICE’s Expert Review Committee concluded that incremental cost effectiveness ratios for Certican in combination with reduced-dose tacrolimus would not be less than £110,000 per QALY gained against any relevant comparator, and thus far outside the realm of what is normally considered value for money.